A detailed history of Columbia Asset Management transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Columbia Asset Management holds 304 shares of REGN stock, worth $224,963. This represents 0.06% of its overall portfolio holdings.

Number of Shares
304
Previous 304 -0.0%
Holding current value
$224,963
Previous $320,000 -0.0%
% of portfolio
0.06%
Previous 0.06%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 05, 2024

BUY
$883.2 - $1071.19 $7,948 - $9,640
9 Added 3.05%
304 $320,000
Q4 2023

Feb 09, 2024

SELL
$775.18 - $881.7 $23,255 - $26,451
-30 Reduced 9.23%
295 $259,000
Q3 2023

Nov 13, 2023

SELL
$692.45 - $844.37 $27,698 - $33,774
-40 Reduced 10.96%
325 $267,000
Q2 2023

Aug 14, 2023

SELL
$700.03 - $830.35 $38,501 - $45,669
-55 Reduced 13.1%
365 $262,000
Q1 2023

May 15, 2023

SELL
$680.49 - $826.97 $170,122 - $206,742
-250 Reduced 37.31%
420 $345,000
Q3 2022

Nov 03, 2022

SELL
$573.97 - $724.32 $11,479 - $14,486
-20 Reduced 2.9%
670 $462,000
Q2 2022

Aug 26, 2022

SELL
$548.35 - $738.84 $416,746 - $561,518
-760 Reduced 52.41%
690 $408,000
Q4 2021

Feb 14, 2022

SELL
$543.48 - $670.97 $54,348 - $67,097
-100 Reduced 6.45%
1,450 $916,000
Q3 2021

Nov 15, 2021

BUY
$574.03 - $680.96 $267,497 - $317,327
466 Added 42.99%
1,550 $938,000
Q2 2021

Aug 02, 2021

BUY
$472.8 - $558.54 $512,515 - $605,457
1,084 New
1,084 $605,000
Q2 2019

Aug 15, 2019

SELL
$299.6 - $414.82 $238,182 - $329,781
-795 Closed
0 $0
Q1 2019

May 20, 2019

BUY
$372.08 - $439.57 $115,344 - $136,266
310 Added 63.92%
795 $326,000
Q3 2018

Nov 06, 2018

BUY
$351.14 - $408.51 $170,302 - $198,127
485 New
485 $196,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $79.3B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Columbia Asset Management Portfolio

Follow Columbia Asset Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Columbia Asset Management, based on Form 13F filings with the SEC.

News

Stay updated on Columbia Asset Management with notifications on news.